AG-METOPROLOL-L TABLET

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Bahan aktif:

METOPROLOL TARTRATE

Tersedia dari:

ANGITA PHARMA INC.

Kode ATC:

C07AB02

INN (Nama Internasional):

METOPROLOL

Dosis:

50MG

Bentuk farmasi:

TABLET

Komposisi:

METOPROLOL TARTRATE 50MG

Rute administrasi :

ORAL

Unit dalam paket:

100/500

Jenis Resep:

Prescription

Area terapi:

BETA-ADRENERGIC BLOCKING AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0111923002; AHFS:

Status otorisasi:

APPROVED

Tanggal Otorisasi:

2018-10-02

Karakteristik produk

_AG-Metoprolol-L tablets _
_Page 1_
_ _
_of 41_
_ _
PRODUCTMONOGRAPH
PR
AG-METOPROLOL-L
Metoprolol Tartrate Tablets USP
25mg, 50 mg and 100 mg film coated tablets,
USP
β-Adrenergic Receptor Blocking Agent
Angita Pharma Inc
1310 rue Nobel
Boucherville, Québec
J4B 5H3, Canada
Submission Control No: 266208
Date
of
Revision:
August 10, 2022
_AG-Metoprolol-L tablets _
_Page 2_
_ _
_of 41_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT
INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
....................................................................................................
4
WARNINGS AND
PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
..................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
12
DOSAGE AND ADMINISTRATION
...............................................................................
18
OVERDOSAGE
.................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 21
STORAGE AND STABILITY
..........................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 25
PART II: SCIENTIFIC
INFORMATION ..................................................................................
26
PHARMACEUTICAL INFORMATION
..........................................................................
26
CLINICAL TRIALS
...................................................................